Cimetidine for Molluscum Contagiosum
Posted: Thursday, April 29, 2010
by Vita Li
Cimetidine is approved by the FDA for the reduction of the secretion of gastric acid. It is used to alleviate the symptoms of peptic ulcer disease, erosive gastroesophageal reflux disease, and hypersecretory conditions including Zollinger-Ellison syndrome and multiple endocrine adenomas. It is available over the counter and by prescription.
Cimetidine can produce significant inhibition of cytochrome P450 isoforms. Clinically relevant interactions include theophylline, aminophylline, metoprolol, nifedipine and quinidine. The interaction involving the beta-blockers, metoprolol and propranolol, results in significant sinus bradycardia and hypotension. It does not interact with atenolol and nadolol.
It can inhibit the metabolism of hydroxyzine and the conversion of dapsone to its toxic hydroxylamine, effects which are beneficial in dermatologic therapy. Oral cimetidine prolongs clarithromycin absorption. Cimetidine has been examined for its antimalarial properties in the presence or absence of chloroquine or pyrimethamine and was found to be synergistic with them.
Cimetidine has immunomodulatory effects that include blocking suppressor T cells and facilitating cell-mediated immunity. The histamine-induced upregulation of IL-6 and IL-8 production, however, may be completely abrogated by a combination of pyrilamine and cimetidine. In patients with allergic rhinitis, cimetidine decreases the number of CD4+ and increases the number of CD8+ lymphocytes.
Cimetidine inhibits nitric-oxide-associated nitrate production in a horse soft-tissue inflammation model. It decreases interleukin 6 production by human keratinocytes. It can block cell proliferation and c-fox gene transcription. It also might have a role in suppressing delayed hypersensitivity reactions. The exact role that these immunological effects play in the treatment of clinical disease has yet to be defined.
Molluscum contagiosum, a common illness in children, caused by a pox virus, has been treated with cimetidine. At a dose of 30-40 mg/kg/day, it has been used as a treatment for children and adults. In two patients, one with 60 lesions and the other with 200 lesions, cimetidine at 40 mg/kg/day in four divided doses for six weeks cleared all lesions. However, other studies find it ineffective.
AntiMolluscum-Rx is composed of naturally occurring high intensity antiviral extracts which have a lethal effect against the virus upon exposure. Application of this molluscum contagiosum treatment provides maximum and rapid penetration of antiviral agents into cell membranes without damaging healthy skin tissue. As a result, this treatment for molluscum enjoys a well earned reputation for its curative effects.
Molluscum occurring anywhere on the body can be successfully eliminated with application of AntiMolluscum-Rx. This product is concentrated with naturally occurring monoterpene aldehydes which have tremendous antiviral effects against the molluscum virus, as demonstrated in published scientific studies.
This is a potent yet safe anti-viral agent for topical use to eradicate molluscum infections. It quantifiably inhibits and kills the molluscum virus. Application of AntiMolluscum-Rx has an immediate therapeutic effect against Molluscum contagiosum and has a positive influence on the immune response.
When treating molluscum, topical application of AntiMolluscum-Rx counters the infection, rapidly utilizing the powerful forces of its monoterpenes. These micro particles in this molluscum contagiosum treatment provide the most rapid absorption; they enter cell membranes with incredible swiftness and have a direct antiviral effect against molluscum.
The lipophilic characteristic of AntiMolluscum-Rx allows it to penetrate deeply. It is absorbed in the skin and into the system in trace quantities. Therefore, this treatment for molluscumnot only has a direct virucidal effect, but provides total systemic support. To learn more, please go to http://www.naturespharma.org .
This Article has been viewed 234 times. (Not updated in real-time.)
No comments yet.We want your comments! If you can read this, you don't have javascript enabled, so you can't use this comment system. Please enable javascript.